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Abstract
Introduction. Statins effect on the outcome of endovascular intervention due to chronic lower limb ischaemia 
(CLLI) is still uncertain. The aim of this study was to determine the effect of statin type on the late outcome of 
superficial femoral artery (SFA) stenting in patients with CLLI. 
Material and methods. Retrospective analysis of the medical documentation of 275 consecutive patients 
treated with SFA stenting due to CLLI, including 125 (45%) patients with critical limb ischaemia (CLI). Meas-
ured outcomes were: target lesion revascularization (TLR), target extremity revascularization (TER), and target 
limb amputation (TLA).
Results. Statins were used by 267 (97%) of the patients, respectively: atorvastatin (n = 191, 70%), simvas-
tatin (n = 31, 11%) and rosuvastatin (n = 45, 16%). During the 675.0 ± 569.7 days of follow-up, TLR was 
required by 79 (29%) patients, TER by 109 (39%), and TLA by 27 (10%). Patients treated with rosuvastatin 
in comparison with those treated with atorvastatin, in spite of greater initial LDL and triglyceride levels, required 
TER (p = 0.01) and TLR (p = 0.03) less frequently. The risk of TER in patients treated with rosuvastatin was 
significantly (p = 0.016) lower than in individuals treated with atorvastatin and simvastatin, as shown in the 
Kaplan-Meier analysis. Cox’s proportional hazards regression showed that therapy with rosuvastatin was the 
strongest factor (HR 0.40 ± 95% CI; 0.2-0.81) decreasing the likelihood of TER.
Conclusions. Rosuvastatin after SFA stenting seems to have the strongest effect on reduction in reintervention 
risk but without influence on limb salvage. 
Key words: chronic lower limb ischaemia, statins, endovascular therapy, superficial femoral artery 
stenting, reintervention risk, amputation risk
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Introduction
Chronic lower limb ischaemia (LLI) is a  chronic 
disorder, which progresses in about 20–30% of cases, 
leading to the shortening of claudication distance to 
a level that limits everyday activity and/or to symptoms 
of critical limb ischaemia (CLI) with rest pain and sleep 
disturbance, necrosis and the need for amputation [1]. 
These symptoms mainly decrease quality of life. How-
ever, they are also related to increased mortality due 
to cardiovascular comorbidities in the other vascular 
beds. These facts determine the aims of the treatment 
of patients with LLI. These aims are mainly a reduction 
in all-cause and cardiovascular mortality, limb salvage 
and improvement in symptoms severity and quality of 
life through the lengthening of claudication distance, 
which allows for increased daily activity and improved 
function. These aims can be achieved by lifestyle 
modification and control of the atherosclerosis risk 
factors (smoking cessation, blood pressure control), 
pharmacotherapy, walking training, and revasculari-
zation (endovascular, surgical or hybrid) [1–3]. The 
main problem with endovascular treatment is the 
recurrence of symptoms due to in-stent restenosis 
(ISR) and/or atherosclerosis progression. A number of 
procedural methods have been proposed to decrease 
the risk of ISR or to treat it when occurs. They are as 
follows: a) the use of a drug-eluting stent (DES) which 
releases anti-proliferative drugs, statins, cytokine and 
growth factor inhibitors, as well as the use of covered 
stents; or b) avoidance of stent implantation by the use 
of a drug-eluting balloon (DEB), a cutting balloon or 
debulking techniques (for various types of atherectomy) 
[2–8]. However, the role of pharmacotherapy for this 
purpose is not well known [3]. In the context of the 
effect of statins on decreasing ISR incidence in patients 
after coronary artery stenting [9, 10] and their diverse 
hypolipidemic and pleiotropic effects [11, 12], we tried 
to assess their efficacy in patients after superficial fem-
oral artery (SFA) stenting. 
Material and methods 
We conducted a retrospective analysis of the medi-
cal documentation (obtained during hospitalization and 
visits in our out-patients clinic) of 275 all, consecutive 
patients treated in our clinic due to chronic LLI with SFA 
stenting as a first revascularization approach between 
1 January 2011 and 31 December 2014. After percuta-
neous revascularization all patients were followed-up 
in our out-patients clinic having performed duplex scan 
of treated limb. The inclusion criteria were as follows: 
SFA stenting, lack of previous vascular interventions in 
stented extremity, and presence on at least one visit in 
our out-patient clinic in 2015. The following data were 
analysed: demographic (e.g. age and gender), clinical 
(e.g. symptom severity), biochemical (e.g. complete 
blood count, creatinine, total cholesterol, low-density 
lipoprotein (LDL) and high-density lipoprotein (HDL) 
cholesterol, triglycerides and blood glucose) and angio-
graphic (TransAtlantic Inter-Society Consensus [TASC] 
classification of femoropopliteal lesions) [1, 2]. 
Measured outcomes 
During the period between the performance of the 
percutaneous procedure and 31 August 2015, the fol-
lowing efficacy outcomes of the analysis were taken: 
target lesion revascularization (TLR), target extremity 
revascularization (TER), and target limb amputation 
(TLA) [13]. TLR was defined as repeat percutaneous 
(endovascular) revascularization for a lesion anywhere 
within a stent or the 5 mm border proximal or distal 
to the stent due to symptom recurrence and target 
lesion occlusion or significant narrowing (mainly due 
to ISR). TER was defined using a wider set of criteria 
than usual [13], as the revascularization of a previ-
ously stented lower limb due to the target lesion or 
a new lesion at least 10 mm outside the proximal or 
distal border of the stent due to symptom recurrence 
(claudication impeding the normal daily functioning 
of the patient or critical limb ischaemia) and lesion 
diameter stenosis ≥ 50% (an effect of atherosclerosis 
progression). TLA was defined as a minor or major 
amputation of a previously stented limb during the 
follow-up period. 
The following safety outcomes were also analysed: 
rhabdomyolysis, acute liver injury, and other adverse 
reactions to statin treatment. 
Bioethics
The study protocol was approved by the local Bio-
ethics Committee (agreement number KB139/2014). 
All procedures were conducted in compliance with the 
Declaration of Helsinki. 
Statistical analysis 
A licensed version of STATISTICA (a data analysis 
software system), version 10 (StatSoft, Inc., 2011) was 
used. The normal distribution of the study variables 
was checked using the Shapiro-Wilk test. The results 
were mainly presented as the mean ± the standard 
deviation (SD) or n, %. The statistical significance of the 
differences between the patient groups was verified in 
relation to the type of variable distribution using para-
metric tests (Student’s t-test, Chi2) if the distribution 
of the variables was normal, and non-parametric tests 
(Mann-Whitney U, Chi2) if not. The association be-
tween the type of statin used and end-point occurrence 
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Table 1. Demographic and clinical characteristics of patients studied in relation to the statin taken (n = 267, 97%)
Feature Atorvastatin 
(n = 191)
Simvastatin 
(n = 31)
Rosuvastatin 
(n = 45)
Age (years) 65.4 ± 10.2 65.4 ± 8.6 64.3 ± 9.5
Male gender (n, %) 123 (64%) 23 (74%) 31 (69%)
Smoking habit (n, %) 99 (52%) 14 (45%) 21 (47%)
Hypertension (n, %) 136 (71%) 22 (71%) 39 (87%)
Diabetes mellitus (n, %) 71 (37%) 14 (45%) 13 (28%)
Dyslipidaemia (n, %) 151 (79%) 21 (68%) 41 (91%)#
BMI [kg/m2] 27.2 ± 5.1 31.4 ± 3.1 24.2 ± 2.1
CAD (n, %) 77 (40%) 19 (61%)* 23 (51%)
Stroke (n, %) 16 (8%) 7 (23%)* 1 (2%)
CHF (n, %) 49 (26%) 10 (32%) 8 (18%)
Creatinine > 2 mg/dL (n, %) 6 (3%) 1 (3%) 0 (0%)
Total cholesterol [mg/dL] 183.8 ± 46.0 166.0 ± 28.8 243.8 ± 55.5#
LDL cholesterol [mg/dL] 122.6 ± 39.1 112.9 ± 36.0 138.1 ± 48.9#
HDL cholesterol [mg/dL] 48.4 ± 9.4 49.3 ± 8.5 61.0 ± 18.4
Triglycerides [mg/dL] 144.3 ± 75.9 138.5 ± 84.0 181.9 ± 85.3#
Fibrate in combination therapy (n, %) 8 (4%) 1 (3%) 3 (7%)
Rutherford classification 4.0 ± 1.2 3.8 ± 1.1 3.7 ± 1.2
ABI of the treated leg 0.53 ± 0.18 0.58 ± 0.16 0.54 ± 0.14
Classification of the treated lesion according to  
TASC-II (B/C/D; n, %)
24 (13%)/
2 (59%)/
55 (29%)
8 (26%)/
14 (45%)/
9 (29%)
8 (18%)/
29 (64%)/
8 (18%)
Number of implanted stents (n) 1.5 ± 0.8 1.3 ± 0.9 1.6 ± 0.75
Sum of stent lengths [mm] 95.2 ± 62.1 89.5 ± 72.4 100.6 ± 66.1
TLR (n, %) 58 (30%) 11 (35%) 9 (20%)#
TER (n, %) 82 (43%) 14 (45%) 10 (22%)#
TLA (n, %) 18 (9%) 5 (16%) 2 (4%)
Number of days between intervention and TLR 358.6 ± 400.9 239.8 ± 240.6 407.8 ± 313.6
Number of days between intervention and TER 262.9 ± 343 ± 340.8 340.8 ± 210.5 389.0 ± 271.4
Number of days between intervention and TLA 657.0 ± 585.4 711.2 ± 503.1 541.6 ± 518.4
BMI — body mass index; CAD — coronary artery disease; CHF — chronic heart failure; LDL — low-density lipoprotein; HDL — high-density lipoprotein; ABI — ankle- 
-brachial index; TASC — TransAtlantic Inter-Society Consensus; TLR — target lesion revascularization; TER — target extremity revascularization; TLA — target limb 
amputation. Statistical significance of difference (p < 0.05): *between atorvastatin and simvastatin groups; #between atorvastatin and rosuvastatin groups
was verified using survival analysis, the Cox’s F test, 
the log-rank test in the Kaplan-Meier method for two 
groups (rosuvastatin vs. atorvastatin vs. simvastatin), 
as well as using Cox’s proportional hazard regression 
analysis. A p-value < 0.05 was considered statistically 
significant. 
Results
In the analysed group, 125 (45%) patients underwent 
SFA stenting due to CLI and 150 (55%) due to inter-
mittent claudication limiting usual daily physical activity. 
In whole group the severity and prevalence of respec-
tive atherosclerosis risk factors during hospitalization 
linked with endovascular procedure were: age (65 ± 
9.8 years), male gender (n = 181, 66%), dyslipidaemia 
(n = 218, 79%), hypertension (n = 202, 73%), smoking 
habit (n = 135, 49%), and diabetes mellitus (n = 101, 
37%). Statins were recommended in discharge cards in 
267 (97%) patients: atorvastatin in 191 (69%), which 
included 151 (55%) patients with a recommended dose 
of 40 mg; simvastatin 40 mg for 31 (11%) patients, 
and rosuvastatin 20 mg for 45 patients (16%). All the 
patients for whom statins were recommended declared 
adherence to the treatment during control visits in 
out-patients clinic. A comparison of demographic and 
clinical data for the groups of patients using the respec-
tive types of statins is presented in Table 1. 
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Table 2. Cox’s proportional hazard regression for the risk of target extremity revascularization (Chi2 = 58.48; p = 0.00002)
Feature b Standard  
error of b
Wald  
statistics
p Hazard ratio  
± 95% CI
Age (years) –0.04 0.01 10.23 0.001 0.96 ± 0.94–0.99
Male gender (n, %) 0.21 0.23 0.85 0.36 1.23 ± 0.79–1.94
Smoking habit (n, %) –0.06 0.22 0.08 0.78 0.94 ± 0.62–1.44
Hypertension (n, %) –0.30 0.25 1.42 0.23 0.74 ± 0.45–1.22
Diabetes mellitus (n, %) 0.48 0.24 4.07 0.04 1.62 ± 1.01–2.58
Dyslipidaemia (n, %) –0.10 0.29 0.12 0.73 0.90 ± 0.51–1.6
BMI [kg/m2] –0.28 0.09 9.74 0.002 0.76 ± 0.63–0.90
CAD (n, %) 0.31 0.26 1.42 0.23 1.35 ± 0.6–1.52
Stroke (n, %) –0.48 0.42 1.29 0.26 0.62 ± 0.27–1.42
CHF (n, %) 0.44 0.28 2.52 0.11 1.56 ± 0.90–2.7
Creatinine > 2 mg/dL (n, %) –1.73 1.05 2.72 0.1 0.18 ± 0.02–1.38
Total cholesterol [mg/dL] –0.002 0.005 0.10 0.75 0.99 ± 0.98–1.01
LDL cholesterol [mg/dL] 0.006 0.003 2.86 0.09 1.01 ± 0.99–1.01
HDL cholesterol [mg/dL] 0.01 0.027 0.24 0.62 1.01 ± 0.96–1.07
Triglycerides [mg/dL] –0.002 0.003 1.14 0.29 0.99 ± 0.99–1.0
Rutherford classification 0.38 0.09 18.44 0.0001 1.46 ± 1.23–1.74
ABI of treated leg –1.39 1.23 1.28 0.26 0.25 ± 0.02–2.78
Classification of the treated lesion 
according to TASC-II (B/C/D; n, %)
–0.21 0.17 1.48 0.22 0.81 ± 0.58–1.14
Number of implanted stents (n) 0.25 0.19 1.81 0.18 1.28 ± 0.89–1.84
Sum of stent lengths [mm] 0.002 0.002 1.24 0.27 1.00 ± 0.99–1.01
Rosuvastatin vs. other statins –0.91 0.36 6.43 0.01 0.40 ± 0.2–0.81
CI — confidence interval; BMI — body mass index; CAD — coronary artery disease; CHF — chronic heart failure; LDL — low-density lipoprotein; HDL — high-
-density lipoprotein; ABI — ankle-brachial index; TASC — TransAtlantic Inter-Society Consensus
Figure 1. The effect of rosuvastatin therapy compared with 
other statins on the risk of target extremity revasculariza-
tion (TER) following endovascular intervention according to 
Kaplan-Meier analysis
During on average 675.0 ± 569.7 days of follow-up 
(median ± low–upper quartile: 630 ± 168–1036 days), 
TLR was required by 79 (29%), TER by 109 (40%), and 
TLA by 27 (10%) patients. Patients treated with rosuvas-
tatin, in spite of higher levels of LDL cholesterol and trigly-
cerides at the day of first endovascular procedure compared 
with individuals treated with atorvastatin, less frequently 
required TER (p = 0.01) and had fewer reinterventions 
considered as TER (22% vs. 43%; p = 0.03) (Tab. 1). 
The prevalence of TLR and TLA in the rosuvastatin group 
of patients was non-significantly lower than in patients 
treated with other statins (the combined group of atorva-
statin and simvastatin) (Tab. 1). In the survival analysis 
(Chi2 = 8.2; p = 0.016), the risk of TER in patients treated 
with rosuvastatin was significantly lower than in patients 
with other hypolipidaemic therapy (Fig. 1). Cox’s pro-
portional hazard regression showed that therapy with 
rosuvastatin was one of the few independent significant 
variables and the strongest factor (0.40 ± 0.2–0.81) de-
creasing the risk of TER in the two-year follow-up (Tab. 2). 
In the medical documentation available for the pa-
tients studied, we did not find any information showing 
the occurrence of any safety outcomes that might be 
related to therapy with statins. 
Discussion
In our case-control retrospective analysis of medical 
documentation of patients treated with SFA stenting 
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due to various severity of chronic LLI, we estimated the 
effect of the type of statin used on primary stent patency 
and the need for revascularization. In other words, we 
checked the influence of statins on ISR and atheroscle-
rosis progression in patients after SFA stenting. In the 
analysed period, 29% of the patients needed TLR due 
to loss of primary stent patency in the course of ISR, 
and 39% required the revascularization of a previously 
stented extremity (TER), which demonstrated that in 
10% of the individuals during the two-year observation 
the clinically important progression of atherosclerosis 
occurred in the extra-stent part of the vascular bed. 
Our results concerning TLR prevalence are similar to 
other reports, which showed that clinically important 
ISR occurred in as many as 18–40% of patients treated 
during the first year after stent implantation [14, 15]. 
In our study, in spite of differences in the number 
of subjects taking the various types of statins, we found 
that patients from the rosuvastatin group had a lower 
risk of reintervention (TLR and TER), which, in rela-
tion to TER, was confirmed by survival analysis (Fig. 1, 
Tab. 2). Such observations suggest an advantage of 
this statin over the other hypolipidaemic drugs in the 
prevention of ISR (TLR) and atherosclerosis progression 
(TER). As patients treated with rosuvastatin had the 
highest LDL blood concentration at the time of the first 
endovascular procedure (Tab. 1), the results obtained 
may be explained by the stronger pleiotropic effect of 
this statin, which, among other things, depends on an 
improvement in endothelial function, endothelial regen-
eration, increased nitric oxide synthesis (vasodilatation 
promotion) and angiogenic effect, reduced oxidant 
stress, inflammation suppression, as well as athero-
sclerosis plaque stabilization [3, 12]. Rosuvastatin has 
also revealed an anti-inflammatory and anti-thrombotic 
effect [16], which is highly important in patients with 
LLI, the majority of whom have increased levels of the 
inflammatory biomarkers linked to ISR prevalence [17]. 
In some previous investigations, the association be-
tween statin use and the patency of arteries in the lower 
extremities at various vascular levels after endovascular 
intervention were examined [3, 18–25], but we did not 
find any data concerning the advantage of using rosuvas-
tatin in the prevention of standard end-point occurrence. 
Some of these works showed that in patients with inter-
mittent claudication and CLI treated endovascularly statin 
use was mainly linked with a decrease in all-cause and 
cardiovascular mortality, as well as cardiovascular event 
(acute coronary syndrome, stroke or death) [3, 19, 20], 
and a smaller number of patients showed a lower risk of 
undesirable end-points related to the treated extremity, 
such as symptom severity, the need for reintervention, 
and amputation (limb events, limb morbidity) [3, 21–24]. 
For example, Dosluoglu et al. [25] showed that of 717 pa- 
tients following endovascular treatment due to LLI, sta-
tin users (55.4%) had better survival in comparison to 
their counterparts, but without significant differences in 
stent patency. A review of earlier publications concern-
ing the effect of statins both on general cardiovascular 
end-points and on the effectiveness of the endovascu- 
lar treatment of LLI was presented by Erez and Leiters- 
dorf [18] and Bonaca and Creager [3]. 
In our patients with chronic LLI, statin use (97%) 
was more prevalent than in other studies (18.7% [3], 
67% [20] and 55.4% [25], respectively). On the other 
hand, our study showed that, in spite of the widely 
known and above-mentioned favourable effects of 
statins, the level of LDL cholesterol recommended 
for patients with very high cardiovascular risk was not 
achieved in the majority of our patients with LLI. In our 
study, the mean LDL blood concentration amounted 
to 124 mg/dL, although a study by Westin et al. [22] 
showed that patients with LDL level > 130 mg/dL had 
increased risk of a combined cardiovascular event and 
mortality compared with patients with lower levels of 
LDL. The European Society for Cardiology recommends 
lowering LDL cholesterol to < 2.5 mmol/L (100 mg/dL) 
for patients with LLI, and optimally to < 1.8 mmol/L 
(70 mg/dL) or ≤ 50% of the initial LDL cholesterol 
level when reaching a  target therapeutic LDL blood 
concentration is impossible [26]. Adherence to these 
therapeutic aims is better in patients with coronary 
artery disease (CAD) than in subjects with LLI [3]. 
In a study by Pereg et al. [27], an LDL level < 100 mg/dL 
was achieved in 65% vs. 47% (p < 0.0001) of CAD 
and LLI patients respectively, and LDL level < 70 mg/dL 
was achieved in 23% vs. 13% (p < 0.0001) of CAD and 
LLI patients, respectively. On the other hand, in Heart 
Protection Study the effect of simvastatin was independ-
ent of initial LDL cholesterol blood concentration and 
other atherosclerosis risk factors [3]. 
Unfortunately, as most authors, we could not avoid 
some methodological shortcomings that could have 
influenced the strength of the deductions based on 
our results. Firstly, our study was performed according 
to a  retrospective medical documentation analysis, 
and without randomization to the respective statin 
treatment, on a relatively small patient group, and with 
the lack of a control group (only 3% of the subjects 
did not take any statins). However, it would not have 
been ethical to perform any investigation on patients 
with cardiovascular disease who are not treated with 
statins. Secondly, we did not know the hypolipidaemic 
effect of the recommended statins in patients in whom 
a renewed endovascular procedure was not necessary. 
We based our results only on the information provid-
ed by patients during monitoring visits, but a  recent 
publication has shown that only 54.3% of patients 
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adhered to their prescription for anti-platelet therapy 
after percutaneous coronary interventions, in spite of 
their declared adherence to the recommended thera-
py [28]. Thirdly, in our group of patients the potential 
confounding factors were not balanced (Tab. 1). On 
the one hand, patients treated with rosuvastatin had 
significantly greater prevalence of dyslipidaemia, as well 
as had higher total, LDL cholesterol, and triglycerides 
blood concentrations, what might act to the disadvan-
tage of this statin. On the other hand, they had slightly 
but not significantly lower prevalence of diabetes, past 
stroke, congestive heart failure and renal insufficiency, 
as well as lover BMI value, which could negatively affect 
the outcomes of atorvastatin compared with rosuvas-
tatin. Nevertheless, we think that our observation of 
rosuvastatin having the most beneficial effect in the 
prevention of ISR and atherosclerosis progression in 
patients with LLI after endovascular intervention is 
worthy of further evaluation. The importance of such 
investigations increases in the context of the favourable 
effect of the use of biodegradable stents eluting rosu-
vastatin in animal models [29]. 
Conclusions
1. Rosuvastatin seems to have the most favourable 
clinical effect on the risk of reintervention after 
SFA stenting, but without influence on limb salvage. 
However, this positive outcome needs to be con-
firmed due to the small size of the group investigated 
and imbalance of the potential confounding factors. 
2. No satisfactory control of lipid-related atheroscle-
rosis risk factors was found in our study in patients 
with chronic LLI. 
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